| Autor: |
Kaur P; School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala, Punjab, India., Ghosh S; Department of Neuroendocrinology and Experimental Hematology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India., Bhowmick A; Department of Biochemistry, Bose Institute, EN Block, Sector V, Bidhannagar, Kolkata, West Bengal 700091, India., Gadhave K; Indian Institute of Technology (IIT) Mandi, Mandi, Himachal Pradesh, India., Datta S; School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala, Punjab, India., Ghosh A; Department of Biochemistry, Bose Institute, EN Block, Sector V, Bidhannagar, Kolkata, West Bengal 700091, India., Garg N; Indian Institute of Technology (IIT) Mandi, Mandi, Himachal Pradesh, India.; Department of Medicinal Chemistry, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India., Mahajan RL; Thapar Institute of Engineering and Technology-Virginia Tech (USA) Centre for Excellence in Material Sciences; Thapar Institute of Engineering and Technology, Patiala, Punjab, India., Basu B; Department of Neuroendocrinology and Experimental Hematology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India., Choudhury D; School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala, Punjab, India.; Thapar Institute of Engineering and Technology-Virginia Tech (USA) Centre for Excellence in Material Sciences; Thapar Institute of Engineering and Technology, Patiala, Punjab, India. |
| Abstrakt: |
The short half-life in the GI tract necessitates an excess of drugs causing side effects of oral formulations. Here, we report the development and deployment of Bacterioboat, which consists of surface-encapsulated mesoporous nanoparticles on metabolically active Lactobacillus reuteri as a drug carrier suitable for oral administration. Bacterioboat showed up to 16% drug loading of its dry weight, intestinal anchorage around alveoli regions, sustained release, and stability in physiological conditions up to 24 hours. In vivo studies showed that oral delivery of 5-fluorouracil leads to increased potency, resulting in improved shrinkage of solid tumors, enhanced life expectancy, and reduced side effects. This novel design and development make this system ideal for orally administrable drugs with low solubility or permeability or both and even making them effective at a lower dose. |
